[HTML][HTML] Safety and immunogenicity of live-attenuated Japanese encephalitis SA 14-14-2 vaccine co-administered with measles vaccine in 9-month-old infants in Sri …

PR Wijesinghe, MRN Abeysinghe, S Yoksan, Y Yao… - Vaccine, 2014 - Elsevier
Introduction To facilitate introduction of live attenuated SA 14-14-2 Japanese encephalitis
vaccine (LJEV) into the National Immunization Programme of Sri Lanka, we evaluated the
safety and immunogenicity of co-administration of LJEV and measles vaccine at 9 months of
age. Serum immune responses were evaluated post-vaccination on days 28, 180, and 365
using JE neutralization test and anti-measles IgG ELISA. Results 278 infants received one
dose of LJEV and measles vaccine. Of these, 257 were eligible for the per-protocol analysis …

[HTML][HTML] Immunogenicity of live attenuated Japanese encephalitis SA 14-14-2 vaccine among Sri Lankan children with previous receipt of inactivated JE vaccine

PR Wijesinghe, MRN Abeysinghe, S Yoksan, Y Yao… - Vaccine, 2016 - Elsevier
Background The performance of live attenuated Japanese Encephalitis SA 14-14-2 vaccine
(CD-JEV) among children previously given inactivated mouse brain-derived JE vaccine
(IMBV) is unknown. We evaluated the safety and immunogenicity of CD-JEV administered to
2-and 5-year-old children in Sri Lanka. Methods In this open-label, single arm trial in the
Colombo District of Sri Lanka, generally healthy children 2 and 5 years of age who had
previously received two and three doses of IMBV, respectively, were administered one dose …
以上显示的是最相近的搜索结果。 查看全部搜索结果